Access to this full-text is provided by MDPI.
Content available from Vaccines
This content is subject to copyright.
Citation: Ziemssen, T.; Groth, M.;
Winkelmann, V.E.; Bopp, T.
Correction: Ziemssen et al. Immune
Response to Initial and Booster
SARS-CoV-2 mRNA Vaccination in
Patients Treated with
Siponimod—Final Analysis of a
Nonrandomized Controlled Clinical
Trial (AMA-VACC). Vaccines 2023, 11,
1374. Vaccines 2024,12, 911.
https://doi.org/10.3390/
vaccines12080911
Received: 2 July 2024
Accepted: 6 August 2024
Published: 12 August 2024
Copyright: © 2024 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
Correction
Correction: Ziemssen et al. Immune Response to Initial and
Booster SARS-CoV-2 mRNA Vaccination in Patients Treated
with Siponimod—Final Analysis of a Nonrandomized
Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374
Tjalf Ziemssen 1, * , Marie Groth 2, Veronika Eva Winkelmann 2and Tobias Bopp 3
1Department of Neurology, Center of Clinical Neuroscience, Carl Gustav Carus University Clinic,
University Hospital of Dresden, Technische Universität Dresden, 01307 Dresden, Germany
2Novartis Pharma GmbH, 90429 Nuremberg, Germany; marie.groth@novartis.com (M.G.);
veronika.winkelmann@novartis.com (V.E.W.)
3Institute for Immunology, University Medical Center of the Johannes Gutenberg University, 55131 Mainz,
Germany; boppt@uni-mainz.de
*Correspondence: tjalf.ziemssen@uniklinikum-dresden.de
The authors would like to make the following corrections to this published paper [
1
].
There was a mistake in the legend and picture for Figure 1. For month 6 for the cohort
“siponimod continuous”, one patient’s data were missing. This also affected the number of
booster patients with identical month 6 and month 1 after the booster visit in the figure
legend (old: 10 booster patients with n = 6 in cohort 1; corrected: 11 booster patients with
n = 7 in cohort 1). The correct legend and figure appear below.
There was a mistake in the legend and picture for Figure 2. The number of booster pa-
tients with identical month 6 and month 1 after the booster visit was wrong (old: 10 booster
patients with n = 6 in cohort 1; corrected: 11 booster patients with n = 7 in cohort 1). The
labels of the x-axis of Figure 2A for month 1 after the booster in the cohort “siponimod
continuous” contained an error (old: n = 16; corrected: n = 14). Furthermore, in the analysis
of total anti-spike antibodies (Figure 2B), patients with an invalid control had been erro-
neously included. This has been corrected in accordance with an amendment to the clinical
study report. The correct legend and figure appear below.
There was a mistake in the legend and picture for Supplementary Figure S1. In
Figure S1A,
one patient’s data were missing at month 6 in the cohort “siponimod con-
tinuous” and have since been added. This change also affected the figure legend: the
explanation on the missing data (*) had to be revised (old: *one sample missing for month 1
and month 6; corrected: *one sample missing for month 1), as well as the number of booster
patients with identical month 6 and month 1 after the booster visit (old: 10 booster patients
with n = 6 in cohort 1; corrected: 11 booster patients with n = 7 in cohort 1). Furthermore,
the explanations on missing data in Figure S1 (*, **) were not clearly assigned to part (B) of
the figure legend. The explanations have been moved up. The correct legend and figure
appear below.
The proportion of patients with SARS-CoV-2-specific T-cell responses in cohort 1
mentioned within the text (Abstract and Results) was inconsistent with the data in Figure 2A
(old text version: 28.5%; corrected text version: 26.7%). The original sentence in the Abstract,
“T-cell responses were seen in 28.5%, 25.0%, and 73.7% at month 6 and in 28.6%, 50.0%, and
83.3% after the booster (cohorts 1, 2, and 3, respectively)”, should be changed to “T-cell
responses were seen in 26.7%, 25.0%, and 73.7% at month 6 and in 28.6%, 50.0%, and 83.3%
after the booster (cohorts 1, 2, and 3, respectively).” The first sentence in Paragraph 3,
Results Section, “SARS-CoV-2-specific T-cell responses were seen in only 28.5% (cohort
1) and 25.0% (cohort 2) at month 6, as well as in 28.6% (cohort 1) and 50.0% (cohort 2) at
month 1 after the booster”, should be updated to “SARS-CoV-2-specific T-cell responses
Vaccines 2024,12, 911. https://doi.org/10.3390/vaccines12080911 https://www.mdpi.com/journal/vaccines
Vaccines 2024,12, 911 2 of 4
were seen in only 26.7% (cohort 1) and 25.0% (cohort 2) at month 6, as well as in 28.6%
(cohort 1) and 50.0% (cohort 2) at month 1 after the booster”.
The authors state that the scientific conclusions are unaffected.
These corrections were approved by the Academic Editor. The original publication
has also been updated.
Vaccines2024,12,xFORPEERREVIEW2of4
Figure1.(A)SARS‐CoV‐2‐specificneutralizingantibodylevelsinU/mL.(B)SARS‐CoV‐2‐specific
serumtotalantibodylevelsinU/mL.Allthepatientswithavailabledatawereincludedinthe
analysis,andindividualvaluesarerepresentedbydots.For11boosterpatients,themonth6visit
andthemonth1aftertheboostervisitwereidentical(cohort1:n=7;cohort2:n=1;cohort3:n=3).
Thebarsshowthemedianvalues;theblackdoedlinesindicateassay‐specificcut‐offsfor
seropositivity;andthegraydoedlinesindicatethemaximalvalueofthequantificationrange.
DMF:dimethylfumarate;GA:glatirameracetate;IFN:interferon‐beta;n:numberofpatientswith
assessments;TF:teriflunomide;andU:units.
Figure 1.
(
A
) SARS-CoV-2-specific neutralizing antibody levels in U/mL. (
B
) SARS-CoV-2-specific
serum total antibody levels in U/mL. All the patients with available data were included in the
analysis, and individual values are represented by dots. For 11 booster patients, the month 6 visit and
the month 1 after the booster visit were identical (cohort 1: n = 7; cohort 2: n = 1; cohort 3: n = 3). The
bars show the median values; the black dotted lines indicate assay-specific cut-offs for seropositivity;
and the gray dotted lines indicate the maximal value of the quantification range. DMF: dimethyl
fumarate; GA: glatiramer acetate; IFN: interferon-beta; n: number of patients with assessments; TF:
teriflunomide; and U: units.
Vaccines 2024,12, 911 3 of 4
Vaccines2024,12,xFORPEERREVIEW3of4
Figure2.(A)T-cellresponsedefinedasthepresenceofSARS-CoV-2-reactiveT-cellsmeasuredby
thesecretionofeitherIFN-,IL-2,orboth(anylevelabovebasalactivity);(B)ELISpot-based
quantificationofT-cellreactivitybycalculationofIFN-stimulationindicestowardsSARS-CoV-2.
Eachdotrepresentsonepatient,andthemediansareindicatedbyhorizontallines.DMF:dimethyl
fumarate;GA:glatirameracetate;IFN:interferon-beta;IFN-:interferon-;n:numberofpatientswith
assessments;PBMC:peripheralbloodmononuclearcell;andTF:teriflunomide.TheT-cellresponse
couldnotbeassessedinthreepatientswiththecontinuedsiponimodtreatment,onepatientinthe
controlgroupatthemonth6visit,andtwopatientsofcohort3atmonth1aftertheboosterbecause
ofinsufficientcellcountsafterPBMCisolation.For11boosterpatients,themonth6visitandthe
month1aftertheboostervisitwereidentical(cohort1:n=7;cohort2:n=1;cohort3:n=3).
Figure 2.
(
A
) T-cell response defined as the presence of SARS-CoV-2-reactive T-cells measured
by the secretion of either IFN-, IL-2, or both (any level above basal activity); (
B
) ELISpot-based
quantification of T-cell reactivity by calculation of IFN- stimulation indices towards SARS-CoV-
2. Each dot represents one patient, and the medians are indicated by horizontal lines. DMF:
dimethyl fumarate; GA: glatiramer acetate; IFN: interferon-beta; IFN-: interferon-; n: number of
patients with assessments; PBMC: peripheral blood mononuclear cell; and TF: teriflunomide. The
T-cell response could not be assessed in three patients with the continued siponimod treatment,
one patient in the control group at the month 6 visit, and two patients of cohort 3 at month 1 after
the booster because of insufficient cell counts after PBMC isolation. For 11 booster patients, the
month 6 visit and the month 1 after the booster visit were identical (cohort 1: n = 7; cohort 2: n = 1;
cohort 3: n = 3).
Vaccines 2024,12, 911 4 of 4
Vaccines2024,12,xFORPEERREVIEW4of4
FigureS1.SARS-CoV-2-specificneutralizingantibodylevelsinU/mLbythetimingofbooster
vaccination.(A)Boostervaccinationbeforemonth6;*onesamplemissingformonth1.(B)Booster
vaccinationaftermonth6;*onesamplemissingformonth6andmonth1afterbooster;and**two
patientsdidnotreceiveaboostervaccination.Allthepatientswithavailabledatawereincludedin
theanalysis,andtheindividualvaluesarerepresentedbydots.For11boosterpatients,themonth
6visitandthemonth1afterboostervisitwereidentical(cohort1:n=7;cohort2:n=1;cohort3:n
=3).Thebarsshowthemedianvalues,andtheblackdoedlinesindicatetheassay-specificcut-off
forseropositivity.DMF:dimethylfumarate;GA:glatirameracetate,IFN:interferon-beta;IU:
internationalunits;n:numberofpatientswithassessments;andTF:teriflunomide.
TheproportionofpatientswithSARS-CoV-2-specificT-cellresponsesincohort1
mentionedwithinthetext(AbstractandResults)wasinconsistentwiththedatainFigure
2A(oldtextversion:28.5%;correctedtextversion:26.7%).Theoriginalsentenceinthe
Abstract,“T-cellresponseswereseenin28.5%,25.0%,and73.7%atmonth6andin28.6%,
50.0%,and83.3%afterthebooster(cohorts1,2,and3,respectively)”,shouldbechanged
to“T-cellresponseswereseenin26.7%,25.0%,and73.7%atmonth6andin28.6%,50.0%,
and83.3%afterthebooster(cohorts1,2,and3,respectively).”Thefirstsentencein
Paragraph3,ResultsSection,“SARS-CoV-2-specificT-cellresponseswereseeninonly
28.5%(cohort1)and25.0%(cohort2)atmonth6,aswellasin28.6%(cohort1)and50.0%
(cohort2)atmonth1afterthebooster”,shouldbeupdatedto“SARS-CoV-2-specificT-
cellresponseswereseeninonly26.7%(cohort1)and25.0%(cohort2)atmonth6,aswell
asin28.6%(cohort1)and50.0%(cohort2)atmonth1afterthebooster.”
Theauthorsstatethatthescientificconclusionsareunaffected.
ThesecorrectionswereapprovedbytheAcademicEditor.Theoriginalpublication
hasalsobeenupdated.
Reference
1. Ziemssen,T.;Groth,M.;Winkelmann,V.E.;Bopp,T.ImmuneResponsetoInitialandBoosterSARS-CoV-2mRNAVaccination
inPatientsTreatedwithSiponimod—FinalAnalysisofaNonrandomizedControlledClinicalTrial(AMA-VACC).Vaccines2023,
11,1374.https://doi.org/10.3390/vaccines11081374.
Disclaimer/Publisher’sNote:Thestatements,opinionsanddatacontainedinallpublicationsaresolelythoseoftheindividual
author(s)andcontributor(s)andnotofMDPIand/ortheeditor(s).MDPIand/ortheeditor(s)disclaimresponsibilityforanyinjury
topeopleorpropertyresultingfromanyideas,methods,instructionsorproductsreferredtointhecontent.
Figure S1.
SARS-CoV-2-specific neutralizing antibody levels in U/mL by the timing of booster vacci-
nation. (
A
) Booster vaccination before month 6; * one sample missing for month 1. (
B
) Booster vacci-
nation after month 6; * one sample missing for month 6 and month 1 after booster; and
** two patients
did not receive a booster vaccination. All the patients with available data were included in the
analysis, and the individual values are represented by dots. For 11 booster patients, the month
6 visit and the month 1 after booster visit were identical (cohort 1: n = 7; cohort 2: n = 1; cohort
3: n = 3). The bars show the median values, and the black dotted lines indicate the assay-specific
cut-off for seropositivity. DMF: dimethyl fumarate; GA: glatiramer acetate, IFN: interferon-beta; IU:
international units; n: number of patients with assessments; and TF: teriflunomide.
Reference
1.
Ziemssen, T.; Groth, M.; Winkelmann, V.E.; Bopp, T. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in
Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines
2023
,
11, 1374. [CrossRef]
Disclaimer/Publisher’s Note:
The statements, opinions and data contained in all publications are solely those of the individual
author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to
people or property resulting from any ideas, methods, instructions or products referred to in the content.
Available via license: CC BY 4.0
Content may be subject to copyright.